December 29, 2016
The failure of Solanezumab is just the latest casualty in a decades-long series of disappointing dementia drug trials.
No comments so far.
Be first to leave comment below.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Jan 17, 2022 0
Jan 1, 2022 0
Dec 22, 2021 0
Stay informed about health care news across Georgia and the nation.
Help us pursue our nonprofit mission with a tax-deductible donation.
EVERY LITTLE BIT HELPS